Extensive Real-World
Experience ACROSS DUPIXENT
In the us, studied in 17 pivotal trials across 5 indications2
Globally,
≈800,000
patients on DUPIXENT
therapy across 5
indications3,a
aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through December 2023.
itch reduction and nodule clearance at Week 241,2
Your first-line systemic choice
a IQVIA SMART Portal Patient Insights as of March 2026.
b The worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, AFRS, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through March 2026.
c ≈96% of commercial PN patients (18+ years of age) nationally are covered for DUPIXENT. ≈83% of commercial PN patient lives have to fail only 1 or 2 prescription topical treatments.
d MMIT Analysis, March 2026. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, lebrikizumab, and nemolizumab.
e Based on available published commercial UM coverage criteria.
The only dual inhibitor of IL-4 and IL-13 signaling in PN
DUPIXENT binds to IL-4 receptor alpha, inhibiting IL-4 and IL-13 induced inflammatory responses1,4
- Dual inhibition helps reduce type 2 inflammation, reduce itch, and achieve nodule clearance1,4-8
The mechanism of dupilumab action has not been definitively established.
Demonstrated safety profile
Most common adverse reactions (incidence ≥2%) in adult patients with prurigo nodularis are nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.1
Attributes and considerations
NOT AN IMMUNOSUPPRESSANT
OR A STEROID1
NO KNOWN DRUG-TO-DRUG INTERACTIONS1
Not metabolized through the liver or excreted through the kidneys
NO INITIAL LAB TESTING OR
ONGOING LAB MONITORING
according to the Prescribing Information1
NO BOXED WARNING1
Please see additional Warnings and Precautions in the
Prescribing Information and Important Safety Information below.
SELECT IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
AD, atopic dermatitis; AFRS, allergic fungal rhinosinusitis; BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis.